University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Won Kim, MD

Won Kim, MD

Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer | Cancer Immunology

Education

The Cooper Union for the Advancement of Science and Art, New York, NY, BS 05/2003, Engineering
Weill Cornell Medical College, New York, NY, MD, 05/2007, Medicine
New York Presbyterian – Weill Cornell Medical Center, New York, NY, Internship, 06/2008, Internal Medicine
New York Presbyterian – Weill Cornell Medical Center, New York, NY, Residency, 06/2010, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 06/2012, Medical Oncology


Professional Experience

  • 2010-2011
    Chief Resident, Department of Medicine, Weill Cornell Medical College
  • 2010-2011
    Clinical Instructor in Medicine, Department of Medicine, Weill Cornell Medical College
  • 2010-2011
    Assistant Attending Physician, New York Presbyterian-Weill Cornell Medical Center
  • 2013-2014
    Clinical Instructor in Medicine, Division of Hematology and Oncology, UCSF
  • 2014-present
    Assistant Clinical Professor, Division of Hematology and Oncology, UCSF
  • 2015-present
    Assistant Clinical Professor, Department of Urology, UCSF
  • 2016-present
    Associate Program Director, Hematology and Oncology Fellowship Program, UCSF

Honors & Awards

  • 1999
    Four Year Full Tuition Merit Scholarship, The Cooper Union
  • 2003
    Tau Beta Pi, the National Engineering Honor Society
  • 2003
    Summa cum laude, The Cooper Union
  • 2007
    Drusin Memorial Prize for Excellence in Medicine, Weill Cornell Medical College
  • 2007
    Noback Award for Excellence in Teaching, Weill Cornell Medical College
  • 2010
    Housestaff Teaching Award from the Graduating Class of 2010, Weill Cornell Medical College
  • 2010
    Skinner Award for Administrative Stewardship, Weill Cornell Medical College
  • 2013
    ASCO/AACR Workshop: Methods in Clinical Cancer Research
  • 2013
    Ronald Rosenberg Endowed Fellowship in Genitourinary Medical Oncology, UCSF
  • 2013
    Simon-Strauss Foundation Grant
  • 2014
    Merit Award, ASCO 2014 Annual Meeting, American Society of Clinical Oncology
  • 2014
    UCSF Prostate Cancer Program Development Research Program Grant, UCSF
  • 2014
    Safeway-Prostate Cancer Foundation Challenge Award
  • 2015
    Prostate Cancer Foundation Young Investigator Award
  • 2016
    NCCN Kidney Cancer Guidelines Panel Member
  • 2016
    UCSF Division of Hematology and Oncology Teaching Award

Selected Publications

  1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 03.
    View on PubMed
  2. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun; 15(6):804-834.
    View on PubMed
  3. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11.
    View on PubMed
  4. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Sep; 7(9):999-1005.
    View on PubMed
  5. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 May; 22(5):503-e43.
    View on PubMed
  6. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13.
    View on PubMed
  7. Kim W, Fong L. Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol. 2017 Jan; 35(1):4-5.
    View on PubMed
  8. Kim W, Ryan CJ. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. J Comp Eff Res. 2016 Jan; 5(1):5-7.
    View on PubMed
  9. Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015 Nov 17; 8(403):ra116.
    View on PubMed
  10. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  11. Kim W, Ryan CJ. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 01; 121(3):361-71.
    View on PubMed
  12. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9.
    View on PubMed
  13. Kim W, Ryan CJ. Friend or foe: the bifunctional role of steroid hormones in prostate cancer. Oncology (Williston Park). 2014 May; 28(5):408, 410.
    View on PubMed
  14. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):23-7.
    View on PubMed
  15. Kim W, Febbo PG. The current and future role of sequenced-based analysis in prostate cancer tretament. Personalized Medicine. 2013; 10(3):257-273.
    View on PubMed
  16. Kim W, Febbo PG. RNA transcription and translation. In Stadler WM ed. Cancer Biology Review: A Case-Based Approach. 2013.
    View on PubMed
  17. Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012 Jun; 13(2):189-200.
    View on PubMed
  18. Gelbman BD, Cham MD, Kim W, Libby DM, Smith JP, Port JL, Altorki NK, Henschke CI, Yankelevitz DF. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol. 2012 May; 7(5):815-20.
    View on PubMed

Go to UCSF Profiles, powered by CTSI